Stock Financial Ratios, Dividends, Split History

ATHN / athenahealth, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)5,821.32
Enterprise Value ($M)5,676.42
Book Value ($M)973.40
Book Value / Share24.09
Price / Book7.35
NCAV ($M)3.90
NCAV / Share0.10
Price / NCAV1,664.57
Share Statistics
Common Shares Outstanding 40,097,805
Common Stock Shares Outstanding 40,100,000
Preferred Stock Shares Outstanding 0
Weighted Average Number Diluted Shares Outstanding Adjustment 800,000
Weighted Average Number Of Shares Outstanding Basic 39,900,000
Weighted Average Number Of Diluted Shares Outstanding 40,700,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.04
Return on Equity (ROE)0.08
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio2.71
Income Statement (mra) ($M)
Sales Revenue Services Net1,188,400,000.00
Numberof Revenue Sources2.00
Operating Income70.60
Net Income53.10
Earnings Per Share Basic1.33
Earnings Per Share Diluted1.31
Cash Flow Statement (mra) ($M)
Cash From Operations241.10
Cash from Investing-204.00
Cash from Financing-204.00
Identifiers and Descriptors
Central Index Key (CIK)1131096
Related CUSIPS
04685W903 04685W953

Split History

Stock splits are used by athenahealth, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

ResMed Inks Deal With athenaHealth on Brightree's eReferral

2018-06-18 zacks
Brightree, the wholly owned subsidiary of ResMed Inc. (RMD - Free Report) , recently entered into a strategic partnership with athenahealth (ATHN - Free Report) , a leading provider of network-enabled services for hospital and ambulatory clients. (52-0)

6 Most Important Things In Business Today

2018-06-07 247wallst
Jet-fuel prices have surged more than 50% over the past year, pushing carriers to raise fares and Delta Air Lines Inc to cut its profit expectations. (73-0)

PRESS DIGEST-New York Times business news - June 7

2018-06-07 reuters
June 7 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. (15-0)

PRESS DIGEST - Wall Street Journal - June 7

2018-06-07 reuters
June 7 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. (35-0)

Maybe It’s Time for Google to Find a Spine - Bloomberg

2018-06-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (110-0)

CUSIP: 04685W103